Results 61 to 70 of about 371,513 (350)
Drug-induced lupus erythematosus has features distinct from primary systemic lupus erythematosus. It can occur with a wide variety of agents that result in the generation of anti-histone or other types of antibodies.
Umut Selamet +5 more
doaj +1 more source
Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis [PDF]
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.
Clarke, Aileen +9 more
core +1 more source
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao +39 more
wiley +1 more source
Determinant Factors of Morbidity in Patients with Systemic Lupus Erythematosus
Introduction: Severity in systemic lupus erythematosus may vary from mild to even fatal consequences. There are no biomarkers to predict the disease’s prognosis.
Margarida Jacinto +3 more
doaj +1 more source
Review of presentations at the 6th European Lupus Meeting 3-5 March 2005. [PDF]
The 6th European Lupus Meeting was held at the Royal College of Physicians of London and was attended by 450 delegates. The conference brought together leading speakers from Europe and North America who reviewed current knowledge and exciting new ...
Bowman, SJ +3 more
core +1 more source
Systemic Lupus Erythematosus [PDF]
Lupus is a serious, potentially life-threatening disease. Its natural history is to culminate in a crescendo of autoimmunity and organ involvement. Difficulty arriving at the diagnosis may delay institution of therapy, which although helpful brings new problems. The fundamental understanding of this disease has made major strides. There is no consensus
openaire +4 more sources
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava +48 more
wiley +1 more source
OBJECTIVES: To determine the serum interleukin-17 (IL-17) levels in childhood-onset systemic lupus erythematosus patients and to evaluate the association between IL-17 and clinical manifestations, disease activity, laboratory findings and treatment ...
Karina de Oliveira Peliçari +7 more
doaj +1 more source
Vitamin D supplementation in systemic lupus erythematosus patients with vitamin D deficiency and insufficiency : the effect on disease activity, fatigue and interferon signature gene expression [PDF]
Background: Vitamin D deficiency is highly prevalent among patients with systemic lupus erythematosus (SLE) [1]. Evidence from multiple studies has shown that vitamin D deficiency in SLE is associated with a higher disease activity [2].
Borg, Andrew +4 more
core +1 more source

